DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-negative Metastatic Breast Cancer|HER2-positive Circulating Tumor Cells
Interventions: DRUG: standard chemo- or endocrine therapy|DRUG: standard chemo- or endocrine therapy + Lapatinib
Sponsor: Prof. W. Janni